Tumor ablation achieves this organically by simultaneously releasing a vast array of canonical tumor-associated antigens (e.g., MUC1, CEA, HER2, NY-ESO-1) alongside a unique set of patient-specific neoantigens generated by the tumor’s individual mutational landscape [26,31]. The gene discussed is CEACAM5; the disease is neoplasm.